In this study, dissolving microneedles (MNs) using polyvinyl alcohol (PVA) and poly (1-vinylpyrrolidone-co-vinyl acetate) (P(VP-co-VA)) as matrix materials were developed for transdermal delivery of rizatriptan benzoate (RB) for acute migraine treatment. In-vitro permeation studies were conducted to assess the feasibility of the as-fabricated dissolving MNs to release RB. Drug skin penetration were tested by Franz diffusion cells, showing an increase of the transdermal flux compared to passive diffusion due to the as-fabricated dissolving MNs having a sufficient mechanical strength to penetrate the skin and form microchannels. The pharmacological study in vivo showed that RB-loaded dissolving MNs significantly alleviated migraine-related response by up-regulating the level of 5-hydroxytryptamine (5-HT) and down-regulating the levels of calcitonin gene-related peptide (CGRP) and substance P (SP). In conclusion, the RB-loaded dissolving MNs have advantages of safety, convenience, and high efficacy over conventional administrations, laying a foundation for the transdermal drug delivery system treatment for acute migraine.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet2018; 39: 1789–1858.
2.
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache2019; 59: 1–18.
BhaktaMTrangVTauraT, et al.Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia2021; 41: 499–514.
7.
HaanesKAEdvinssonL. Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS Drugs2019; 33: 525–537.
8.
YücelYCoşkunSCengizB, et al.Association of polymorphisms within the serotonin receptor genes 5-HTR1A, 5-HTR1B, 5-HTR2A and 5-HTR2C and migraine susceptibility in a Turkish population. Clin Psychopharm Neu2016; 14: 250–255.
9.
VillalónCMVanDenBrinkAM. The role of 5-hydroxytryptamine in the pathophysiology of migraine and its relevance to the design of novel treatments. Mini Rev Med Chem2017; 17: 928–938.
10.
FangLShanHYinP, et al.Design, synthesis, and structure–Activity relationship studies of novel tryptamine derivatives as 5–HT1B receptor agonists. J Mol Struct2022; 1265: 133320.
11.
FerrariMDGoadsbyPJRoonKI, et al.Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia2002; 22: 633–658.
12.
BenemeiSCorteseFLabastida-RamírezA, et al.School of advanced studies of the European headache federation (EHF-SAS), triptans and CGRP blockade-impact on the cranial vasculature. J Headache Pain2017; 18: 103.
13.
GiniatullinR. 5-hydroxytryptamine in migraine: the puzzling role of ionotropic 5-HT3 receptor in the context of established therapeutic effect of metabotropic 5-HT1 subtypes. Br J Pharmacol2022; 179: 400–415.
14.
MathewPGKleinBC. Getting to the heart of the mater: migraine, triptans, DHE, ditans, CGRP antibodies, first/second-generation gepants, and cardiovascular risk. Headache2019; 59: 1421–1426.
15.
LáinezMJA. Rizatriptan in the treatment of migraine. Neuropsychiatric Dis Treat2006; 2: 247–259.
16.
HuangP-CYangF-CChangC-M, et al.Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment. Prog Brain Res2020; 255: 99–121.
17.
SeahBCTeoBM. Recent advances in ultrasound-based transdermal drug delivery. Int J Nanomed2018; 13: 7749–7763.
18.
GaddumJH. The stability of watery solutions of the oxytocic principle of the pituitary gland. Biochem J1930; 24: 939–944.
19.
RamachandranR. Neurogenic inflammation and its role in migraine, Semin. Immunopathol2018; 40: 301–314.
20.
Carballo-QuintásMMartínez-SilvaICadarso-SuárezC, et al.Study of neurotoxic biomarkers, c-fos and GFAP after acute exposure to GSM radiation at 900 MHz in the picrotoxin model of rat brains. Neurotoxicology2011; 32: 478–494.
21.
BohárZFejes-SzabóATarL, et al.Evaluation of c-Fos immunoreactivity in the rat brainstem nuclei relevant in migraine pathogenesis after electrical stimulation of the trigeminal ganglion. Neurol Sci2013; 34: 1597–1604.
22.
CetinkayaAKilincECamsariC, et al.Effects of estrogen and progesterone on the neurogenic inflammatory neuropeptides: implications for gender differences in migraine. Exp Brain Res2020; 238: 2625–2639.
23.
Keny 1RVDesouzaCLourencoCF. Formulation development and evaluation of orally disintegrating tablets rizatriptan benzoate. Indian J Pharmaceut Sci2010; 72: 79–85.
24.
KassemAA. Formulation approaches of triptans for management of migraine, curr. Drug Deiv2016; 13: 882–898.
25.
ChokshiAVaishyaRInavoluR. Formulation and evaluation of rizatriptan benzoate mouth disintegrating tablets. Int J Pharm2019; 571: 118702.
26.
PerDjupeslandGMessinaJCMahmoudRA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv2014; 5: 709–733.
27.
GirotraPSinghSK. Multivariate optimization of rizatriptan benzoate-loaded solid lipid nanoparticles for brain targeting and migraine management. AAPS PharmSciTech2017; 18: 517–528.
28.
KevinI. Recent progress in transdermal sonophoresis. Pharmaceut Dev Technol2017; 22: 247–259.
29.
RuanLGaoSZhangX, et al.Transdermal delivery of multifunctional CaO2@Mn-PDA nanoformulations by microneedles for NIR-induced synergistic therapy against skin melanoma. Biomater Sci2021; 9: 6830–6841.
30.
WaghuleTSinghviGDubeySK, et al.Microneedles: a smart approach and increasing potential for transdermal drug delivery system. Biomed Pharmacother2019; 109: 1249–1258.
31.
WuDQuanYKamiyamaF, et al.Improvement of transdermal delivery of sumatriptan succinate using a novel self-dissolving microneedles array fabricated from sodium hyaluronate in rats. Biol Pharm Bull2015; 38: 365–373.
32.
NalluriBNSai SriVABramhiniSR, et al.In vitro skin permeation enhancement of sumatriptan by microneedles application. Curr Drug Deliv2015; 12: 761–769.
33.
MenonIBagwePKeeganGomesB, et al.Microneedles: a new generation vaccine delivery system. Micromachines2021; 12: 435.
34.
AmarnaniRShendeP. Microneedles in diagnostic, treatment and theranostics: an advancement in minimally-invasive delivery system, Biomed. Microdevices2022; 4: 24.
35.
HanSLeePChoiH-J. Non-invasive vaccines: challenges in formulation and vaccine adjuvants. Pharmaceutics2023; 15: 2114.
36.
ZhangZLiWChangD, et al.A combination therapy for androgenic alopecia based on quercetin and zinc/copper dual-doped mesoporous silica nanocomposite microneedle patch. Bioact Mater2022; 24: 81–95.
37.
PermanaADNainuFMoffattK, et al.Recent advances in combination of microneedles and nanomedicines for lymphatic targeted drug delivery, Wires. Nanomed. Nanobi2021; 13: e1690.
38.
WuDKatsumiHQuanYS, et al.Permeation of sumatriptan succinate across human skin using multiple types of self-dissolving microneedle arrays fabricated from sodium hyaluronate. J Drug Target2016; 24: 752–758.
39.
SullivanSPKoutsonanosDGMartinMDP, et al.Dissolving polymer microneedle patches for influenza vaccination. Nat Med2010; 16: 915–920.
40.
JungJHSungJinG. Microneedle for transdermal drug delivery: current trends and fabrication. J. Pharm. Investig2021; 4: 503–517.
41.
ChenJRenHPanZ, et al.Microneedle-mediated drug delivery for cutaneous diseases. Front Bioeng Biotechnol2022; 10: 1032041.
42.
KavyaHRBhattacharyyaS. Statistical optimization and evaluation of a multi release unit bilayer tablet of rizatriptan benzoate. Indian J Pharmaceut Sci2021; 83: 52–59.
43.
XuNZhangMXuW, et al.Swellable PVA/PVP hydrogel microneedle patches for the extraction of interstitial skin fluid toward minimally invasive monitoring of blood glucose level. Analyst2022; 147: 1478–1491.
44.
NejadHRAydinSKiaeeG, et al.Low-cost and cleanroom-free fabrication of microneedles. Microsyst Nanoeng2018; 15: 17073.
45.
ShettyDYarlagaddaDLBrahmamB, et al.Investigating the influence of the type of polymer on sustaining the supersaturation from amorphous solid dispersions of Apremilast and its pharmacokinetics. J Drug Deliv Sci Technol2023; 84: 104520.
46.
NguyenHXNguyenCN. Microneedle-mediated transdermal delivery of biopharmaceuticals. Pharmaceutics2023; 15: 277.
47.
RaskMBKnoppMMOlesenNEet al.Influence of PVP/VA copolymer composition on drug–polymer solubility. Eur J Pharmaceut Sci2016; 85: 10–17.
48.
MartinsLMFragaGNPellaM, et al.Poly(1-vinylpyrrolidone-co-vinyl-acetate)-based electrospun dissolvable nanofibrous film for quercetin administration. Process Biochem2022; 122, 8–15.
49.
LiuTChenMFuJ, et al.Recent advances in microneedles-mediated transdermal delivery of Protein and peptide drugs. Acta Pharm Sin B2021; 11: 2326–2346.
50.
Jordan A StinsonAVBCieslewiczBMZhangY, et al.Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles. Vaccine2021; 39: 5410–5421.
51.
NiuLChuLYBurtonSA, et al.Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response. J Contr Release2019; 294: 268–278.
52.
PengKLalitkumarVoraKTekkoIA, et al.Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: potential for enhanced treatment of cutaneous fungal infections. J Contr Release2021; 339: 361–380.
53.
NguyenHXBozorgBDKim 1Y, et al.Poly (vinyl alcohol) microneedles: fabrication, characterization, and application for transdermal drug delivery of doxorubicin. Eur J Pharm Biopharm2018; 129: 88–103.
54.
OlesenJJansen-OlesenI. Towards a reliable animal model of migraine. Cephalalgia2012; 32: 570–580.
55.
Rui-Hai ZhouWHF. The antiplatelet effects of nitrates: is it of clinical significance in patients with cardiovascular disease. Cardiol Rev2010; 18: 129–135.
56.
HouMLiuHLiY, et al.Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics. Eur J Clin Pharmacol2019; 24: 1369–1378.
57.
ManjuladeviRThamilselvanMSelvasekarapandianS, et al.Mg-ion conducting blend polymer electrolyte based on poly(vinyl alcohol)-poly (acrylonitrile) with magnesium perchlorate. Solid State Ionics2017; 308: 90–100.
58.
PoySYBashirSOmarFS, et al.Poly (1-vinylpyrrolidone-co-vinyl acetate) (PVP-co-VA) based gel polymer electrolytes for electric double layer capacitors (EDLC). J Polym Res2020; 27: 50–60.
59.
LeonardAtanaseIBistacaSGérard Riess. Effect of poly(vinyl alcohol-co-vinyl acetate) copolymer blockiness on the dynamic interfacial tension and dilational viscoelasticity of polymer–anionic surfactant complex at the water–1-chlorobutane interface. Soft Matter2015; 11: 2665–2672.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
